New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareVesilute vs Vilon

Vesilute vs Vilon

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Vesilute
Immune SupportAnti-Aging & Longevity
Vilon
Summary
Vesilute is a tetrapeptide bioregulator (Lys-Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific for the retina and visual system. It supports retinal cell function, promotes normalization of photoreceptor protein synthesis, and is studied for age-related macular degeneration (AMD), retinal aging, and vision preservation in the elderly.
Vilon is a synthetic dipeptide (Lys-Glu) derived from the thymus gland extract Thymalin. The shortest immune-regulatory peptide known, Vilon modulates T-cell and NK-cell function, extends lifespan in animal models, and shows epigenetic anti-aging activity. It is one of the Khavinson peptide bioregulators.
Half-Life
Short (minutes); sustained gene-regulatory effects
Very short as a free dipeptide; effects mediated via gene regulation
Admin Route
SubQ, Oral
SubQ, Oral
Research
Typical Dose
10 mg per day
1–2 mg SC daily or 5–10 mg oral daily
Frequency
Daily for 10–30 days
Once daily
Key Benefits
  • Supports retinal photoreceptor cell function and survival
  • May slow progression of age-related macular degeneration
  • Reduces retinal cell apoptosis from oxidative stress and aging
  • Anti-aging effects on retinal pigment epithelium
  • Potential support in diabetic retinopathy management
  • Preserves visual acuity with aging
  • Complementary to lutein, zeaxanthin, and NAD+ in ocular health protocols
  • Immune system modulation and restoration
  • Lifespan extension (30–40% in animal studies)
  • T-cell and NK-cell activation
  • Epigenetic anti-aging activity
  • Reduces oxidative stress markers
  • Antioxidant gene upregulation
  • May prevent age-related immune senescence
  • Anti-tumor immune surveillance
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant ocular adverse events reported at standard doses
  • Excellent safety profile, decades of Russian clinical use
  • Rare: mild injection site reaction
  • Very rare: mild allergic reaction
Stacks With